Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Adc Therapeutics Sa (ADCT)

16.11   0.66 (4.27%) 01-26 00:43
Open: 15.44 Pre. Close: 15.45
High: 16.69 Low: 15.35
Volume: 236,229 Market Cap: 1,236M
ADC Therapeutics SA, a clinical-stage oncology-focused biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its lead product candidates are loncastuximab tesirine (ADCT-402), an ADC that is in a Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma, and Phase III clinical trial in combination with rituximab to treat relapsed or refractory DLBCL, as well as Phase I/II clinical trial in combination with ibrutinib for relapsed or refractory DLBCL and mantle cell lymphoma; and camidanlumab tesirine (ADCT-301), an ADC that is in a pivotal Phase II clinical trial for the treatment of relapsed or refractory Hodgkin lymphoma and non-Hodgkin lymphoma, and Phase Ib clinical trial for selected advanced solid tumors. The company also develops clinical-stage product candidates, such as ADCT-601 that is in a Phase Ia clinical trial for the treatment of selected advanced tumors; and ADCT-602, and a Phase I/II clinical trial for relapsed or refractory acute lymphoblastic leukemia, as well as preclinical product candidates, including ADCT-701 and ADCT-901 for the treatment of selected advanced solid tumors. It has a collaboration and license agreement with Genmab A/S, Bergenbio AS, and Synaffix B.V. ADC Therapeutics SA was incorporated in 2011 and is headquartered in Epalinges, Switzerland.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 16.709 - 16.82 16.82 - 16.92
Low: 15.13 - 15.264 15.264 - 15.385
Close: 15.897 - 16.114 16.114 - 16.31

Technical analysis

as of: 2022-01-25 4:21:55 PM
Stoxline posted a BUY today, upgraded from lower rating. Upward movement to be expected.
Target: Six months: 22.21     One year: 26.30
Support: Support1: 13.34    Support2: 11.10
Resistance: Resistance1: 19.01    Resistance2: 22.52
Pivot: 18.07
Moving Average: MA(5): 15.93     MA(20): 18.62
MA(100): 23.84     MA(250): 24.48
MACD: MACD(12,26): -1.44     Signal(9): -1.17
Stochastic oscillator: %K(14,3): 24.07     %D(3): 13.43
RSI: RSI(14): 29.96
52-week: High: 32.00  Low: 13.34  Change(%): -43.6
Average Vol(K): 3-Month: 192  10-Days: 285

Price, moving averages and Bollinger Bands

Price and moving averages has closed above its Short term moving average. Short term moving average is currently below mid-term; AND below long term moving averages. From the relationship between price and moving averages; we can see that: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
ADCT has closed above bottom band by 22.5%. Bollinger Bands are 32.9% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Headline News

Thu, 20 Jan 2022
ADC Therapeutics to Host Webcast Highlighting its ADC Platform and Solid Tumor Pipeline on February 8, 2022 - Business Wire

Tue, 18 Jan 2022
ADC Therapeutics Announces Exclusive License with Mitsubishi Tanabe Pharma Corporation to Develop and Commercialize ZYNLONTA® (loncastuximab tesirine-lpyl) in Japan - Business Wire

Wed, 03 Nov 2021
ADC Therapeutics SA (ADCT) Q3 2021 Earnings Call Transcript - Motley Fool

Fri, 29 Oct 2021
ADC Therapeutics Announces Validation of its Marketing Authorization Application by the European Medicines Agency for ZYNLONTA® - Business Wire

Wed, 29 Sep 2021
Overland ADCT BioPharma Announces First Patient Dosed in China with ZYNLONTA® in Pivotal Phase 2 Clinical Trial for Diffuse Large B-cell Lymphoma - Business Wire

Mon, 27 Sep 2021
ADC Therapeutics Doses First Patient in Phase 1 Clinical Trial of ADCT-901 in Advanced Solid Tumors - Business Wire

Financial Analysis

Growth NA
Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability NA
Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.
Solvency NA
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency NA
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Price to Book Value: Outperform Discounted cash flow: Outperform
Return on Assets: Underperform Price to Earnings: Underperform
Return on Equity: Underperform Debt to Equity: Outperform
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NYSE
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M) 77
Shares Float (M) 29
% Held by Insiders 51.35
% Held by Institutions 43.60
Shares Short (K) 5,660
Shares Short P. Month (K) 5,850

Stock Financials

EPS -3.280
EPS Est This Year
EPS Est Next Year
Book Value (p.s.) 2.440
Profit Margin
Operating Margin -1636.74
Return on Assets (ttm) -29.8
Return on Equity (ttm) -89.3
Qtrly Rev. Growth
Gross Profit (p.s.) -1.849
Sales Per Share 0.220
EBITDA (p.s.) -3.595
Qtrly Earnings Growth
Operating Cash Flow (M) -223
Levered Free Cash Flow (M) -124

Stock Valuations

PE Ratio -4.91
PEG Ratio
Price to Book value 6.60
Price to Sales 73.09
Price to Cash Flow

Stock Dividends

Forward Dividend
Dividend Yield
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
7 Binary Options
Your Ad Here
Stock Chart
Stoxline Lite
Stoxline Pro
Option Calculator
(c) 2006-2020 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.